CMV in critically ill patients: Pathogen or bystander?

Reviews in Medical Virology

Volumn 20, Issue 6, 2010, Pages 372-379

  Limaye, Ajit P ^a   Boeckh, Michael ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOKINE; GANCICLOVIR; INTERLEUKIN 6; INTERLEUKIN 8; VALGANCICLOVIR;

ACUTE LUNG INJURY; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CRITICALLY ILL PATIENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HISTOPATHOLOGY; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; LENGTH OF STAY; LUNG BIOPSY; LUNG FIBROSIS; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SEPSIS; SEROPREVALENCE; VIRUS DETECTION; VIRUS PNEUMONIA; VIRUS REACTIVATION; VIRUS REPLICATION;

CRITICAL ILLNESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; INTENSIVE CARE UNITS; RISK FACTORS; VIRUS ACTIVATION;

EID: 77958579312     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.664     Document Type: Review

References (51)

1. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 2009; 37(8): 2350-2358.
2. Hamprecht K, Baumeister A, Beck R, Haeberle H, Heininger A. The lung as a central compartment of active CMV infection. Inflamm Res 2007 (Suppl 2): S242 (Abstract A383).
3. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300(4): 413-422.
4. Domart Y, Trouillet JL, Fagon JY, Chastre J, Brun-Vezinet F, Gibert C. Incidence and morbidity of cytomegaloviral infection in patients with mediastinitis following cardiac surgery. Chest 1990; 97(1): 18-22.
5. Papazian L, Fraisse A, Garbe L, et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 1996; 84(2): 280-287.
6. Stephan F, Meharzi D, Ricci S, Fajac A, Clergue F, Bernaudin JF. Evaluation by polymerase chain reaction of cytomegalovirus reactivation in intensive care patients under mechanical ventilation. Intensive Care Med 1996; 22(11): 1244-1249.
7. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998; 26(5): 1076-1082.
8. Cook CH, Yenchar JK, Kraner TO, Davies EA, Ferguson RM. Occult herpes family viruses may increase mortality in critically ill surgical patients. Am J Surg 1998; 176(4): 357-360.
9. Desachy A, Ranger-Rogez S, Francois B, et al. Reactivation of human herpesvirus type 6 in multiple organ failure syndrome. Clin Infect Dis 2001; 32(2): 197-203.
10. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med 2001; 29(3): 541-547.
11. Razonable RR, Fanning C, Brown RA, et al. Selective reactivation of human herpesvirus 6 variant a occurs in critically ill immunocompetent hosts. J Infect Dis 2002; 185(1): 110-113.
12. Cook CH, Martin LC, Yenchar JK, et al. Occult herpes family viral infections are endemic in critically ill surgical patients. Crit Care Med 2003; 31(7): 1923-1929.
13. Jaber S, Chanques G, Borry J, et al. Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest 2005; 127(1): 233-241.
14. von Muller L, Klemm A, Weiss M, et al. Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis 2006; 12(10): 1517-1522.
15. Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med 2008; 36(12): 3145-3150.
16. Chiche L, Forel JM, Roch A, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med 2009; 37(6): 1850-1857.
17. Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care 2009; 13(3): R68.
18. Papazian L, Doddoli C, Chetaille B, et al. A contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients. Crit Care Med 2007; 35(3): 755-762.
19. Papazian L, Thomas P, Bregeon F, et al. Open-lung biopsy in patients with acute respiratory distress syndrome. Anesthesiology 1998; 88(4): 935-944.
20. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342(18): 1334-1349.
21. Levitt JE, Gould MK, Ware LB, Matthay MA. The pathogenetic and prognostic value of biologic markers in acute lung injury. J Intensive Care Med 2009; 24(3): 151-167.
22. Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010; 137(2): 288-296.
23. Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005; 33(1): 1-6; discussion 230-232.
24. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342(18): 1301-1308.
25. Carlquist JF, Edelman L, Bennion DW, Anderson JL. Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-kappaB. J Infect Dis 1999; 179(5): 1094-1100.
26. Compton T, Kurt-Jones EA, Boehme KW, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003; 77(8): 4588-4596.
27. Murayama T, Ohara Y, Obuchi M, et al. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1- and NF-kappaB-binding sites of the interleukin-8 gene. J Virol 1997; 71(7): 5692-5695.
28. Craigen JL, Yong KL, Jordan NJ, et al. Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology 1997; 92(1): 138-145.
29. Iwamoto GK, Konicek SA. Cytomegalovirus immediate early genes upregulate interleukin-6 gene expression. J Invest Med 1997; 45(4): 175-182.
30. Tong CY, Bakran A, Williams H, Cuevas LE, Peiris JS, Hart CA. Association of tumour necrosis factor alpha and interleukin 6 levels with cytomegalovirus DNA detection and disease after renal transplantation. J Med Virol 2001; 64(1): 29-34.
31. Humar A, St Louis P, Mazzulli T, et al. Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients. J Infect Dis 1999; 179(2): 484-488.
32. Humbert M, Devergne O, Cerrina J, et al. Activation of macrophages and cytotoxic cells during cytomegalovirus pneumonia complicating lung transplantations. Am Rev Respir Dis 1992; 145(5): 1178-1184.
33. Humbert M, Delattre RM, Fattal S, et al. In situ production of interleukin-6 within human lung allografts displaying rejection or cytomegalovirus pneumonia. Transplantation 1993; 56(3): 623-627.
34. Boeckh M, Nichols WG. Immunosuppressive effects of beta-herpesviruses. Herpes 2003; 10(1): 12-16.
35. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996; 23(3): 468-474.
36. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103(2): 106-113.
37. Rand KH, Pollard RB, Merigan TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 1978; 298(17): 951-953.
38. Chatterjee SN, Fiala M, Weiner J, Stewart JA, Stacey B, Warmer N. Primary cytomegalovirus and opportunistic infections. Incidence in renal transplant recipients. JAMA 1978; 240(22): 2446-2449.
39. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81(12): 1645-1652.
40. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185(3): 273-282.
41. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100(13): 4358-4366.
42. Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003; 75(2): 229-233.
43. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2(3): 112-117.
44. Flechner SM, Avery RK, Fisher R, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66(12): 1682-1688.
45. Winston DJ. Prevention of cytomegalovirus disease in transplant recipients. Lancet 1995; 346(8987): 1380-1381.
46. Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150(1): 146-152.
47. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365(9477): 2105-2115.
48. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81(2): 139-145.
49. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8(1): 69-77.
50. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8(5): 975-983.
51. Forster MR, Trgovcich J, Zimmerman P, et al. Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice. Antiviral Res 2010; 85(3): 496-503.